Article Information
History
- March 30, 2022.
Article Versions
- Version 1 (March 18, 2022 - 11:43).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Caroline Korves, ScD1,*,
- Hector S. Izurieta, MD, MPH, PhD2,
- Jeremy Smith, MS1,
- Gabrielle M. Zwain, BA1,
- Ethan I. Powell, BA1,
- Abirami Balajee, MPH, BS, BA1,
- Kathryn Ryder, MD, MS3 and
- Yinong Young-Xu, ScD, MA, MS1,4
- 1White River Junction Veterans Affairs Medical Center, White River Junction, VT
- 2Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, White Oak, MD
- 3Veterans Affairs Pacific Island Health Care
- 4Geisel School of Medicine at Dartmouth, Hanover, NH
- ↵*Corresponding author; email: caroline.korves{at}va.gov
Posted March 30, 2022.
Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis
